Biohack Your Way To Beauty And Health Using Your DNA And Stem Cells At These Wellness Retreats Around The World – Singapore Tatler

(Image: Four Seasons) By Chloe Pek October 11, 2019

Need a different type of getaway? From DNA and blood testing to harvesting your own stem cells, these facilities might make you want to forgo your usual spa retreats

Sign up for our weekly newsletter to get all our top stories delivered

Were on Facebook and Instagram. Follow us for the latest news, events and happenings

With so many resorts offering customised retreats tailored to every individual, today's well-travelled spa-goers are no longer satisfied with one-size-fits-all programmes. But beyond personalising activities and treatments to your fitness goals, these destinations are taking bespoke programmes to the next levelones that look into your genetic makeup and medical health to "biohack" your way to beauty and wellness.

(Related: The Tatler 10: Asia's Top Wellness Retreats)

Surrounded by the tropical rainforest in Nusa Dua, south Bali, Revivo Wellness Resort is an intimate retreat that offers 16 Balinese-style suites within three villas. The resort offers a regular schedule of three-day immersive programmes depending on individual goals, from relaxation to weight loss, as well as bespoke retreat programmes. And if you would like to take the personalisation to the next level, Revivo offers three DNA-centric plans that you can add to your programme.

In collaboration with DNA test provider GenePlanet, the Nutrifit and Nutrifit Premium plans offer individually tailored nutritional advice and lifestyle plans, based on your unique DNA makeup. Youll also return with a comprehensive report with analysis from up to 58 different DNA tests to facilitate your wellness goals. Beauty junkies can opt for the Nutriskin plan, which advises on skincare rituals, cosmetics, and diets to achieve optimum skin health.

revivoresorts.com

Surrounded by tropical gardens and white-sand beaches on Mexicos beautiful Riviera Nayarit, the newly renovated Four Seasons Resort Punta Mita offers guest rooms and suites, as well as private beach-front retreats for travellers. Besides a breathtaking oceanside golf-course, the resort also boasts the award-winning Apuane Spa, offering everything from signature massages to holistic therapies.

It is also the only spa in Four Seasons collection that offers DNA testing. Based on results from a simple cheek swab, wellness curators at the resort will create a custom programme that is tailored to your fitness goals and optimal for your genetic makeup, with recommendations to improve your health and diet.

fourseasons.com

(Related: 5 Women's Only Retreats For The Solo Female Traveller)

A preventive health and anti-ageing clinic in Switzerland, Nescens Clinique de Genolier is a luxury destination for medical tourists, overlooking Lake Geneva and the Alps. Programmes include La Cure Nescens, targetted at weight loss; Better-Aging Program which targets lifestyle issues like weight loss, fitness, detox and stress through spa treatments; and the new Nescens Stem Cell Advanced Program, which harnesses your own stem cells to combat signs of ageing.

The programme comprises a very in-depth check-up that includes physical examination, laboratory tests, diagnostic imaging, and cardiology to detect any underlying conditions. Then, following medical consultations with the specialists, a plastic surgeon will extract lipid content via liposuction. Your own stem cells are then separated and re-injected into problem areas together with lipofilling and hydrating mask treatments, to stimulate collagen production and reduce fine lines and wrinkles.

nescens.com

Tucked in a secluded cove by the Caribbean sea, BodyHoliday Saint Lucia is an all-inclusive fitness and spa resort that offers an extensive collection of wellness amenities, including an Ayurvedic temple, wellness centre, freshwater pools, fitness studios, as well as a BodyScience Clinic.

The clinics BodyScience Plus programme offers an in-depth analysis that begins prior to your arrival, requiring guests to complete an online health survey, DNA tests, and other diagnostics recommended by the clinics doctors, such as blood and urine tests. When you arrive, you will receive a personalised plan that will include Ayurvedic meals, a schedule of activities such as yoga, personal training or meditating, and also spa treatments. The programmes are specific to various wellness goals such as digestive health, weight loss, detox, destress and more.

thebodyholiday.com

More:
Biohack Your Way To Beauty And Health Using Your DNA And Stem Cells At These Wellness Retreats Around The World - Singapore Tatler

Man with at least 17 children sues fertility clinic for being ‘incredibly irresponsible’ with his sperm – Genetic Literacy Project

An Oregon doctor filed a $5.25 million lawsuit [October 2] against a fertility clinic at the Oregon Health & Science University for being incredibly irresponsible with his sperm.

Dr. Bryce Cleary, 53, alleges that the OHSU clinic used his 1989 sperm donation to father at least 17 childrensome who live in his areadespite him making an agreement with the clinic at the time that his sperm would be used for no more than five children, all born to women living out of the state.

Dr. Cleary, who lives in Corvallis, learned that at least two of his unexpected biological children conceived through the clinic have attended the same schools, as well as church and social activities, as some of the children he has with his wife.

The idea that you can produce that many children from one donor and throw them all in the same region? Cleary said inan emotional statement at a news conference. There has got to be some reforms.

In his lawsuit, filed in Multnomah County Circuit Court, Cleary says he is profoundly distressed and is grappling with the moral, legal, ethical, and personal obligations to his many children.

Read full, original post: After discovering he has at least 17 kids, man sues fertility clinic

More here:
Man with at least 17 children sues fertility clinic for being 'incredibly irresponsible' with his sperm - Genetic Literacy Project

I donated my embryos years ago. Now I’m friends with the mom who received them – Yahoo Lifestyle

In 2005 I donated embryos, and nine months later, the fertility clinic kindly informed me that the transfer had taken, and a twin girl and boy were born. I felt grateful for the news. In 2013 I heard from the clinic again, this time informing me of two new updates.

1. A third child was born in 2009. (Theyd forgotten to send the news at the time.)2. The recipient was satisfied that her family was complete, and rather than donating the eggs to stem cell science as is customary, she wanted to know if I wanted my cryogenically preserved embryos back.

Beyond the wondrous surprise of the email, the thoughtfulness of a stranger quietly holding this possibility for me felt like a cosmic miracle. I was touched by the idea of the potential children that might be born of these embryos one unlikely day, but more than that, I was moved by this anonymous persons generosity and grace. I instantly felt a deep connection when we began corresponding through a website for anonymous donors and recipients.

When the mother and I first started emailing each other, I was thrilled by the chance to connect with this person and exchange stories, which she was so utterly generous with. I made a point of taking my cues from her, never pushing for any information, and mostly listening. This woman had been so thoughtful about me, all these years, while I had no idea. Possibly, this is why our communication brought instant honesty. Once the embryos were transferred back to me, the mother wrote kindly about wanting to tell me that, thanks to details revealed in my donor profile and picturesmainly my devotion to writing, my deep gayness, and my look of short messy hair, tortoiseshell glasses, cuffed jeans, and a popped collarshe already had a deep sense of me.

undefined

The mother and I entered into a consistent correspondence, and more than once she shared with me her gratitude for what she called this immaculate coupling that has created three perfect beingshealthy, loving, smart, their unborn siblings sure to follow suit. She expressed joy at being able to help another woman (me!) work on her career, unfettered by any biological imperative to raise children within a particular timeline. Then she opened up about the twins, a boy and a girl, and the youngest, a girl, a sibling configuration very similar to my own family.

In another email she shared a story with me about going to a yard sale with the three kids. Her stories gave me the sense that the girl and her twin both were a bit androgynous, and the younger sister was described as a quiet, pensive tomboyjust like my own sister. I laughed to myself, thinking that maybe queerness was genetic and all the cryobabies would be queer. When this problematic idea crossed my mind, I smiled at the intersection of biology and identity and some kind of science fiction-level genetic technology that I dont really understand beyond how it feels to have gone through the donation process, medically and emotionally, and how much wonder I feel in the face of the connection born between us. The mother also recounted a story of the girl twin heading straight to the section of boys clothes, where for $10 she amassed an entire back-to-school wardrobe embodying, the boyish, preppy look of Shiloh Jolie-Pitt crossed with KD Lang, to add a more tasteful flair. The mother wrote about being secretly proud, a feeling I experienced reading her secondhand account.

A few months into our pen-pal relationship, our conversations about turned more precisely to gender, trans identity, and the nuanced fluidity of the child self, uncontainable within ideological notions of gender, imposed through words and systems far too restrictive for a child. I learned the girl twin had started playing around with different pronouns at age three, eventually settling on she, and living out her own exact aesthetic and social selves under the loving watch of her utterly attentive mother.

When the mother asked about my own experiences with gender, I sent her links to Psychology Today blogs I had written about this very topic. Quickly she responded, My first reaction to your literary contributions is that Im proud of you, before going on to marvel that, I never thought in a million years that your writing would become my future child-rearing material.

From all the anecdotes and details she shared with me, I had a clear mental image of all three children, and an automatic, indescribable sense of identification with the one child in particular. Through our communications about this childs gender, the mother and I were able to connect on a level I can only describe as spiritual.

undefined

I felt the call of these stories wishing to be told by our genes, and I continue to feel it in every cell in my body, despite having no specific words to share with this child and her siblings. Of all the anecdotes and images shared with me, here is the one that breaks me open every time I remember the early email where I learned details about the girl twin.And here I am, the mother had written, on the cusp of offering to reveal my life and giving a part of myself to someone Ive never met but I have. She is with us every day, her smile, her quirkiness, her drive, her cropped hair and Clark Kent glasses, her confusion, her revelations and rebirths, I have met her.

Reading this, I wiped the tears fogging up my Clark Kent glasses, my reflection glancing back at me in the glow of the screenmy cropped hair, my popped collar, my entire sense of self at once affirmed and exploded.

Read the original:
I donated my embryos years ago. Now I'm friends with the mom who received them - Yahoo Lifestyle

Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 – The Ukiah Post

Global Parkinsons Disease Treatment Market 2019-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Get 10% Discount: https://www.adroitmarketresearch.com/contacts/discount/615

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report at https://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 972-362-8199/ +91 9665341414

Here is the original post:
Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 - The Ukiah Post

Stem cell therapy helped Owen Franks but there’s still plenty to prove – Stuff.co.nz

Stem cell therapy, which All Blacks prop Owen Franks used to help fix a damaged shoulder, is raising hopes of a whole range of medical breakthroughs.

But there's a way to go before the medical establishment is convinced.

In late 2017, US Food and Drug Administration (FDA) Commissioner ScottGottliebhad this to say:"We're at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease."

REGEN CELLULAR

Dr Hassan Mubark takes blood from All Blacks prop Owen Franks.

Yet, as an indication of how far there is still to go, the FDA has also warnedpeople in the USagainst "unscrupulous providers" offering stem cell products that were unapproved and unproven.

READ MORE:*Rugby World Cup 2019: All Black Owen Franks thrown a stem cell lifeline*Owen Franks hits back at critics following omission from Rugby World Cup squad*Stem cell therapy for All Black Israel Dagg as he hits comeback trail with Crusaders*Experimental stem cell treatment shows results for Waikato woman with MSA Cerebella*Stem cell clinics accused of taking advantage of patients*Reported stem cell treatment could give hope to Michael Schumacher

"Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases," it said, thenadded: "Stem cells have been called everything from cure-alls to miracle treatments. But don't believe the hype."

Looking at just the area of deteriorating joints, it's easy to see how stem cell therapies, if they deliver on the promise,could make life much better for many people with osteoarthritis who are in pain and have restricted movement.

Last week, Otago University researchers predictedthe number of knee replacement surgeries needed for osteoarthritis would increase from around 5000 a year in 2013 to abut9000 in 2038.

AP

Former Formula One champion Michael Schumacher received devastating head injuries in a ski accident six years ago. Last month it was reported he has undergone stem cell treatment in Paris.

Osteoarthritis is the area where ReGen Cellular,the clinic where Franks had the therapy, has done most of its work in the past two to three years, although ithas recently expanded its services to include a range of diagnosed auto-immune conditions, among them rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.

ReGensaid 55 per cent of its patients were aged over 60, 35 per cent were 40-60 and 10 per cent were sports-based.

Theclinic usesPure Expanded Stem Cell (PESC) therapy, which involves taking 40 grams - about a teaspoon - of fat from around a patient's stomach. Mesenchymal stem cells (MSCs)in that sample are then multiplied in the clinic's Queenstown laboratory for about eight weeks. At the end of that process 100 million to 200 million cells have been produced.

Otago University

Otago University, Christchurch regenerative medicine research team have invented a bio-ink - a gel-like substance mixed with human stem cells - to be used with a bio-printer to make human body parts. Video shows the printer using bio-ink to make a body part.

For the treatment of osteoarthritis, between 50m and 100m stem cells are injected into larger joints, with 25m to 50m into smaller joints. ReGen said the therapy provided immediate pain reduction and increased mobility. MRI scans showed cartilage could and did regenerate.

ReGendescribedMSCs as the cells that "wake up damaged or lazy cells". Slightly more technically, Nature.com said MSCs wereadult stem cells present in multiple tissues, including the umbilical cord, bone marrow and fat.MSCscan self-renew by dividing and can differentiate into multiple tissues including bone, cartilage, muscle and fat cells, and connective tissue.

ReGen director of patient care Marcelle Noble said the clinic believed its treatments, if offered early enough, would save the public health system hundreds of millions of dollars through lessened replacement surgeries, and would save ACC millions of dollars in lengthy rehabilitation programmes.

The treatment for two knees was half the price of one knee replacement surgery within the public health system, she said. ReGen advertises osteoarthritis treatment for a single joint at $12,500 and for two joints at $15,000.

GETTY IMAGES

Former All Black Israel Dagg had stem cell therapy for an injured knee, but in the end had to give the game away because of the injury.

So far mainstream funding hadnot been offered for the therapy, Noble said. But the clinic had a "big breakthrough" earlier this year when two insurers in New Zealand accepted patients'PESC therapy claims. In July, ACC accepted consultation by ReGen's chief medical officer Dr Hassan Mubark.

ReGen only had data for the past five years on the success of its therapy, but the fact patients were returning to have other areas of their body treated was an indication of how people feltthe therapy was improving their quality of life, Noble said.

Globally, "massive" R&D spending was going into stem cell research. More therapies would become available and stem cell treatment would become "commonplace".

At any one time ReGen had 50-75 patients' cells growing in its incubators, Noble said. Of the patients treated, 40 per cent hadailments in therknees, 30 per cent in their hips, 20 per cent in their shoulders. The final 10 per cent were for sports and other issues, including problems with tendons, muscles, cartilage tears, fingers, elbows, ankles and hands.

SUPPLIED

Dr Ron Lopert undergoing part of the PESC treatment.

The first patient to undertake ReGen's PESC therapy was retired GP Dr Ron Lopert, who lives in Tauranga.

For five to 10 years, he had beengetting aches and pains in his hips after playing sport, and the problem was becoming more noticeable, he said. In 2013 he had an x-ray that showed he had moderate to severe osteoarthritis in both hips,more severein his right hip.

He stopped playing all sports and started researching different forms of treatment. Ideally, he wanted to be able to get some of his own cartilage back and reverse the osteoarthritis. It seemedPESCshould do that.

In 2015, aged 61, he had the therapy, with stem cells being injected into each hip joint.Within weeks henoticed an improvement in the range of motion and a decrease in pain, Lopert said.Some of that was just the anti-inflammatory component of stem cell injection, but he thought he also received a longer term benefit from cartilage regeneration.

SUPPLIED

Dr Lopert on his recent travels. He says he has much less hip pain.

He put the success of the procedure at75 per centin terms of symptoms and function, and100 per cent when it came to avoiding invasive surgery."I opted for a much more natural treatment where my own tissue is regenerating, instead of a metal prosthesis," Lopert said.

He was not sure all the improvement came from the stem cell treatment. As well as avoiding overuse of the joints, which meant he hadn't returned to playing sport, he had also switched to an anti-inflammatory diet.

His left hip continued to have hardly any symptomsbut he had started noticing the "odd twinge now and then" in his right hip.

"The vast majority of days it's fine provided I'm just walking and doing ordinary things. On the odd occasion I might carry something heavy, then I would notice it the next day and it (right hip) would stay painfulintermittentlyfor the next couple of days," Lopert said.

Sean Gallup

In this picture from February, German Chancellor Angela Merkel looks through a microscope at brain organoids grown from stem cells.

Some of his stem cells had been retained after the treatment, and he was booked in for a follow-up injection for his right hip at the end of October.

He expected the therapy would become a "go to" treatment, and would become an early intervention for osteoarthritis. But more independent research was needed to confirm the success of the treatment. "The evidence is slowly building up but there needs to be more before the Government will accept it," Lopert said.

In his case, he thought there had been cartilage regeneration in his hips, but that was based on his symptoms. "It would have been nice had I had MRI scans before and after the injection for objective evidence," he said.

From the perspective of the medical establishment, the New Zealand Orthopaedic Association said it supported a position statement on stem cell therapy produced by the Royal Australian College of Surgeons.

That paper, approved in mid-2018,noted stem cell therapy was a "rapidly advancing" area, but many proposed stem cell therapies were experimental and not yet proven. It did not support surgeons administering stem cell therapy outside of an ethically approved registered clinical trial.

"Whilst there may be scope for innovative treatment in the future, currently, the clinical effectiveness and safety of stem cell therapies remain scientifically unproven," RACS said.

In this country, an ACC spokesperson said ACC did not have an official position on stem cell therapy for the treatment of injuries. An internationally standardised evidence-based healthcare approach was used to help ACC decide how it covered injuries and funded treatments.

Dr HassanMubark, ReGen's chief medical officer, was a healthcare provider contracted to ACC in the specialty of rheumatology, and ACC had funded consultation fees with Mubark, the spokesperson said. Those consultations were for diagnostic and treatment planning purposes and did not need prior approval from ACC.

ACC had to consider legislative criteria when deciding whether to fund any particular treatment. There would be many reasons why ACC might decide to fund a client to see a rheumatologist for an opinion on the diagnosis and possible management of their condition. That would not commit ACC to funding any proposed treatment but would provide the client and ACC with information to help decision-making.

Continue reading here:
Stem cell therapy helped Owen Franks but there's still plenty to prove - Stuff.co.nz

Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma – Cancer Therapy Advisor

First-line autologous stem cell transplant (ASCT) is cost-effective in patients with newly diagnosed multiple myeloma (MM) but more research is needed to assess cost-effectiveness of other, newer antimyeloma regimens in different treatment-line settings, according to a systematic review of studies from 11 countries published over the past quarter of a century. The analysis was published in the journal PharmacoEconomics.

For transplant-eligible MM patients, transplant isa cost-effective first-line treatment, reported senior study author ProfessorDavid R. Lairson, PhD, co-director of the Center for Health Services Researchat the University of Texas MD Anderson Cancer Center in Houston, and coauthors.

However, the evidence for the relative costeffectiveness of other treatment regimens remains unclear and more research isneeded, the researchers noted. Second-line bortezomib-based regimens,lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost-effectivecompared with dexamethasone alone but which of these combinatorial regimens isthe most cost-effective remains unclear.

MM incidence rates have climbed in recent years, asbaby boomers aged into late adulthood. MM treatment strategies have beenchanging rapidly over recent years, as well, thanks to newly approved agentsand treatment regimens. Newer regimens are promising and benefit some patients;however, none are considered curative.

Previous systematic reviews have compared specifictherapies. However, few comprehensive cost-effectiveness analyses have beenundertaken that compare available therapies across treatment lines.

To compare the cost effectiveness of treatmentregimes, the authors searched research literature databases and identified 24such assessments, published between 1990 and 2018, summarizing incrementalcost-effectiveness ratio (ICER), quality-adjusted life-year (QALY), andlife-year gained (LYG) for different treatment regimens and treatment lines(first-line, second-line, and multiple-line treatments).

Unpublished literature, including someindustry-sponsored studies and reports, or non-English reports, were notincluded, cautioned the researchers. In addition, 2 studies were not availablein the databases searched and their exclusion from the analysis might havebiased their results, the team acknowledged.

Four studies included in the review had comparedtransplant and no-transplant treatments cost-effectiveness. Amongtransplant-eligible patients, first-line transplant was the mostcost-effective option, with an ICER of at least $4053 per QALY gained andbetween $3848 and $72,852 per LYG. Compared with conventional chemotherapy,first-line novel agents (bortezomib, thalidomide, and lenalidomide) had an ICERof $59,076 per QALY gained and $220,681 per LYG. ASCT in patients with new diagnoseswas cost effective compared with melphalan, the researchers reported (ICER of $25,710per LYG).

Second-line novel agent regimens had inconsistentICERs, the researchers reported.

More cost-effectiveness analyses comparing novelagents in the first-line treatment regimen are warranted to determine whichagent or regimen is the most cost-effective, the researchers concluded.

[T]he papers included in this review were conductedfrom different perspectives, countries, and years, and using differentcost-effectiveness criteria, the researchers noted. [R]eaders need to usecaution when interpreting the conclusions in the context of their localjurisdiction and cost-effectiveness criteria.

Multiple myeloma caused 12,590 deaths in 2017,representing 2% of all US cancer deaths.

Reference

This article originally appeared on Oncology Nurse Advisor

Here is the original post:
Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma - Cancer Therapy Advisor

AgeX Therapeutics to Present at Metabesity 2019 – Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, PhD will deliver a presentation titled The Age-Related Metabolic Program as part of a session at Metabesity 2019, October 15-16 in Washington, DC.

Details of the session follow.

Wednesday, October 16Carnegie Institution for Science 1530 P Street NWWashington, DC 20005

9:40-10:45am Panel Session: Clinical Development Issues Challenges and Opportunities

Dr. West will be joined on the panel by:

The full event program is available here.

A copy of the presentation will be available on the Investors section of the companys website at http://www.agexinc.com.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform named induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in AgeXs reports filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View original post here:
AgeX Therapeutics to Present at Metabesity 2019 - Business Wire

BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – ElliotLakeToday.com

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

View post:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - ElliotLakeToday.com

Fred Hutch scientist on how gold nanoparticles could bring CRISPR to the developing world – GeekWire

Jennifer Adair, a senior scientist at Fred Hutch, speaks at the 2019 GeekWire Summit. (GeekWire Photo / Kevin Lisota)

Genetically editing cells using CRISPR could be the answer to curing genetic disorders such as sickle cell anemia. But in order for the technology to be available for people in countries like Nigeria where around a quarter of the population carries the sickle cell trait the technology will need to become substantially cheaper and less invasive.

Thats where gold nanoparticles come in.

Scientists at the Fred Hutchinson Cancer Research Center are devising an approach that vastly simplifies how CRISPR is applied. Their goal is to create a safe process for gene editing that takes place entirely within the body of a patient.

In order to edit human stem cells using CRISPR today, scientists have to follow a process that involves removing the cells from a patients bone marrow, electrocuting those cells, and modifying them with engineered virus particles.

The process gets even more invasive from there. We actually have to treat these patients with chemotherapy, radiation or other agents in order for these cells that were genetically manipulated to be taken up, Jennifer Adair, a senior scientist at Fred Hutch, said during a talk at the 2019 GeekWire Summit.

The researchers think theyve figured out the first step, which is delivering CRISPR to blood stem cells inside the body. Theyre doing that using gold nanoparticles that are about a billionth the size of a grain of table salt and able to smuggle in RNA, DNA and a protein.

Weve been able to show that not only can we make these, but they passively deliver all of those components to blood stem cells, then we do get genetic editing. And weve been able to go on to show that we can correct the sickle cell defect using this approach, said Adair.

The nanoparticles are big enough to carry the CRISPR payload but small enough to infiltrate cell membranes. Gold is a useful medium since it isnt harmful to humans.

The Fred Hutch team published their work with gold nanoparticles earlier this year in the journal Nature Materials. The system safely edited 10 to 20 percent of the target cells, which the researchers hope will increase as the method is refined.

In an ideal world, clinicians would be able to deliver gene therapy through a syringe, a process that might be accomplished in a single office visit. Adair previously published research on agene therapy in a box concept, a table-top device that could provide gene therapy treatments without the need for expensive medical infrastructure.

We need to develop technologies that make gene editing simpler, more affordable and more accessible to patients around the world, Adair said.

See the original post here:
Fred Hutch scientist on how gold nanoparticles could bring CRISPR to the developing world - GeekWire

Recognizing the LGBTQ+ community at Stanford: "We should be a beacon" – Scope

Carolyn Dundes came to Stanford Medicine to learn about brain development and stem cell biology, not to be a spokesperson for gender minorities.

Some days, Dundes, a second-year PhD student, doesn't have the energy to teach people that "transgender" means the gender you were assigned at birth doesn't match the one you identify with. Nor does Dundes always feel comfortable correcting people who use the wrong gender pronouns. Dundes identifies as gender nonbinary, which is to say not male or female, and uses the gender neutral they/them pronouns instead of "she" or "he."

But Monday, at Stanford Medicine's second annual LGBTQ+ Forum, Dundes embraced the opportunity to share how the Stanford Medicine community could step up as allies of gender-nonconforming peers and colleagues. Providing all-gender restrooms and sharing your preferred personal pronouns are two steps everyone can take to support sex and gender minorities, they pointed out.

The forum provided a platform to discuss how medical education, research and care at Stanford could be more inclusive of lesbian, gay, bisexual, transgender and queer/questioning individuals.

"These are challenging times in our country and they are particularly challenging for our LGBTQ+ community," said Dean Lloyd Minor, MD. "We should be a beacon. We should be a model in demonstrating our commitment in achieving a more diverse and inclusive society. It has to begin right here at home."

Mitchell Lunn, MD, and Juno Obedin-Maliver, MD, co-directors of the PRIDE Study, the first national long-term health of LGBTQ+ health, delivered the keynote address.

Obedin-Maliver, an obstetrician/gynecologist, and Lunn, a nephrologist, met as medical students at Stanford in 2005 and joined the faculty earlier this year.

They've been thinking about LGBTQ+ health care needs since they began medical school. As lesbian and gay students, they were interested in learning more about how to take care of themselves and their community, and found little in the curriculum, Obedin-Maliver said.

"Our own communities were really invisible in our medical training," she said.

After surveying other medical schools and determining how little was being taught nationwide, Obedin-Maliver and Lunn determined there was a need for more data around how being a sex and/or gender minority influences a person's physical, mental and social health. That led to the launch of the PRIDE Study. Currently 16,000 people have enrolled in the landmark study, which conducts annual wide-ranging health questionnaires.

Lunn encouraged researchers in the audience to consider including more LGBTQ+ people in studies, give participants a way to report their gender or sexuality when they join a study and think about how they can involve the people they're trying to help in the research process.

Following panels discussing LGBTQ+ issues in clinical and research environments, the event concluded with closing remarks by Minor; David Entwistle, president and CEO of Stanford Health Care; and Paul King, president and CEO of Stanford Children's Health.

Minor said he would continue to support events that foster LGBTQ+ inclusion and invited the audience to share feedback for the leadership

Obedin-Maliver said it meant a lot to have Minor, King and Entwistle in the room. She asked that they allow staff to include gender pronouns on their clinical badges and require all staff and faculty members be trained on unique health needs in the LGBTQ+ population.

King, CEO of Lucile Packard Children's Hospital, gave his word that initiatives like Monday's forum would continue until they were no longer necessary.

"You shouldn't have to train everyone in terms of the issues that you face," King said. "When we come into a community, we want to see ourselves -- we want to be welcomed."

Photos by Luke Girard / Thru Luke's Lens; Mitchell Lunn shown at top

Read more here:
Recognizing the LGBTQ+ community at Stanford: "We should be a beacon" - Scope